Anaplastic astrocytoma (historical)
Citation, DOI and article data
Anaplastic astrocytomas are a historical term used to denote histological grade III diffuse astrocytic tumors (regardless of molecular markers). The term has been removed and is no longer recognized as a distinct entity as of the 5th edition (2021) of the WHO classification of CNS tumors 5.
Tumors once considered anaplastic astrocytomas are be classified as either astrocytoma IDH-mutant grade 3 or grade 4 tumors or glioblastoma grade 4 according to their molecular characteristics (see astrocytic tumors)
The histological features of anaplastic astrocytomas were intermediate between those of diffuse low-grade astrocytomas (WHO grade II) and what was then termed glioblastomas (WHO IV)
Note: the term glioblastoma as it is currently used does not equate to how it was used prior to the 5th edition of the WHO classification.
The key features present in anaplastic astrocytomas that were absent in low-grade tumors were mitotic activity and cellular pleomorphism. Unlike glioblastomas, however, they did not demonstrate necrosis or vascular proliferation.
CT appearances were intermediate, appearing as regions of low attenuation with positive mass effect. Enhancement was variable.
Anaplastic astrocytomas appeared similar to low-grade astrocytomas but were more variable in appearance.
The key to distinguishing anaplastic astrocytomas from low-grade tumors was the presence of enhancement which should generally be absent in the latter 1.
Unlike glioblastomas, anaplastic astrocytomas lacked frank necrosis 1.
- T1: hypointense compared to white matter
- T2: generally hyperintense but can be heterogeneous in cases with blood calcification
- T2-FLAIR: relative hypointensity of most of the tumor except a hyperintense rim (T2-FLAIR mismatch sign)
T1 C+ (Gd)
- very variable but usually at least some enhancement was present
- presence of ring enhancement suggested central necrosis and thus glioblastoma rather than anaplastic astrocytoma
- increased choline-to-creatine ratio
- NAA preserved or mildly depressed
- no significant lactate
- intermediate levels of myo-inositol (lower than low grade, but higher than GBM) 2
- MR perfusion: elevated cerebral blood volume
Treatment and prognosis
Compared to glioblastomas, there were relatively few trials looking at treatment regimens for anaplastic astrocytoma 3. General principles were the same, however, with surgical resection when possible being the treatment of choice with or without subsequent radiotherapy and/or chemotherapy. This depends on the treating clinician's preference, the degree of resection, patient demographics and whether or not the tumor has recurred.
As is the case with everything about anaplastic astrocytomas, the prognosis was also intermediate between low-grade astrocytomas and glioblastomas. Typically patients succumbed to their tumor in 2-3 years, often with transformation into a glioblastoma 4.
The differential, given the heterogeneous and variable appearance of these tumors, was relatively wide and included:
- other astrocytomas
- often multiple
- located at grey-white matter junction
- absent NAA, absent myo-inositol
- ring enhancement
- older age group
- subacute cerebral infarct
- gyriform enhancement
- vascular territory
- open ring enhancement
- 1. Atlas SW. Magnetic Resonance Imaging Of The Brain And Spine. Lippincott Williams & Wilkins. (2009) ISBN:078176985X. Read it at Google Books - Find it at Amazon
- 2. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol. 2000;21 (9): 1645-9. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 3. Principles and Practice of Stereotactic Radiosurgery. Springer. (2008) ISBN:0387710701. Read it at Google Books - Find it at Amazon
- 4. DeVita VT, Lawrence TS, Rosenberg SA. Devita, Hellman & Rosenberg's cancer [electronic resource]. Lippincott Williams & Wilkins. (2008) ISBN:0781772079. Read it at Google Books - Find it at Amazon
- 5. Ellison DW, Aldape KD, Capper D et al cIMPACT-NOW update 7: advancing the molecular classication of ependymal tumors. Brain Pathology 30 (2020) 863–866 doi:10.1111/bpa.12866
- 6. Louis D, Perry A, Wesseling P et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro-Oncology. 2021;23(8):1231-51. doi:10.1093/neuonc/noab106 - Pubmed